Página principal > Resultados de la búsqueda: Wu, Yi
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 4 registros encontrados en 0.02 segundos.
Artículos, Encontrados 4 registros
Artículos Encontrados 4 registros  
1.
11 p, 379.4 KB Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC / Wu, Yi-Long (Guangdong Lung Cancer Institute) ; John, Thomas (Austin Health) ; Grohe, Christian (Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (University of California) ; Kim, Sang-We (University of Ulsan) ; Kato, Terufumi (Kanagawa Cancer Center) ; Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ; Vu, Huu Vinh (Choray Hospital) ; Wang, Zhije (Chinese Academy of Medical Sciences) ; Lu, Shun (Shanghai Jiao Tong University) ; Lee, Kye Young (Konkuk University Medical Center) ; Akewanlop, Charuwan (Siriraj Hospital) ; Yu, Chong-Jen (National Taiwan University College of Medicine) ; de Marinis, Filippo (European Institute of Oncology) ; Bonanno, Laura (Istituto Oncologico Veneto) ; Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ; Shepherd, Frances A. (University of Toronto) ; Zeng, Lingmin (AstraZeneca) ; Atasoy, Ajlan (AstraZeneca) ; Herbst, Roy S. (Yale School of Medicine) ; Tsuboi, Masahiro (National Cancer Center Hospital East) ; Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 - 10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433  
Registro completo - Creative Commons
2.
10 p, 9.7 MB The development and structure of the mesentery / Byrnes, Kevin. G. (University of Limerick, Ireland) ; Walsh, Dara (University of Limerick, Ireland) ; Walsh, Leon G. (University of Limerick, Ireland) ; Coffey, Domhnall M. (University of Limerick, Ireland) ; Ullah, Muhammad F. (University of Limerick, Ireland) ; Mirapeix, Rosa (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Hikspoors, Jill (Maastricht University, Netherlands) ; Lamers, Wouters (Maastricht University, Netherlands) ; Wu, Yi (Third Military Medical University, Chongqing, China) ; Zhang, Xiao Qin. (Third Military Medical University, Chongqing, China) ; Zhang, Shao Xiang (Third Military Medical University, Chongqing, China) ; Brama, Pieter (School of Veterinary Medicine. Veterinary Science Centre, Dublin, Ireland) ; Dunne, Colum P. (University of Limerick, Ireland) ; O'Brien, Ian S. (National University of Ireland Galway) ; Peirce, Colin B. (University of Limerick, Ireland) ; Shelly, Martin J. (University of Limerick, Ireland) ; Scanlon, Tim G. (University of Limerick, Ireland) ; Luther, Mary E. (University of Limerick, Ireland) ; Brady, Hugh D. (University of Limerick, Ireland) ; Dockery, Peter (National University of Ireland Galway, Ireland) ; McDermott, Kieran W. (University of Limerick, Ireland) ; Coffey, J.Calvin (University of Limerick, Ireland)
The position of abdominal organs, and mechanisms by which these are centrally connected, are currently described in peritoneal terms. As part of the peritoneal model of abdominal anatomy, there are multiple mesenteries. [...]
2021 - 10.1038/s42003-021-02496-1
Communications Biology, Vol. 4 Núm. 1 (august 2021) , p. 982  
Registro completo - Creative Commons
3.
11 p, 421.8 KB Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ; John, Thomas (Department of Medical Oncology. Austin Health) ; Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ; Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ; Kim, Sang-We (Department of Oncology. Asan Medical Center) ; Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ; Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ; Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ; Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ; Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ; Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ; Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ; Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ; Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ; Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ; Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ; Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296  
Registro completo - Creative Commons
4.
9 p, 1.3 MB A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer / Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences) ; Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; John, T. (Department of Medical Oncology. Austin Health) ; Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, J.W. (David Geffen School of Medicine. University of California) ; Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences) ; Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine) ; Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, H.V. (Department of Thoracic Surgery. Choray Hospital) ; Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center) ; Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS) ; Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto) ; Zeng, L. (Late Oncology Statistics. AstraZeneca) ; Hodge, R. (Late Oncology Statistics. AstraZeneca) ; Atasoy, A. (Late Oncology Research and Development. AstraZeneca) ; Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca) ; Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. [...]
2021 - 10.2217/fon-2021-0752
Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835  
Registro completo - Creative Commons

Vea también: autores con nombres similares
219 Wu, Y.
1 Wu, Y. Q.
1 Wu, Y.Q.
3 Wu, Ya Q.
1 Wu, Yajiang
3 Wu, Yang
1 Wu, Yaru
3 Wu, Yi-Long
1 Wu, Yingzh
1 Wu, Yingzhe
1 Wu, Yonghong
1 Wu, Yongjiang
2 Wu, Yu-Tzu
1 Wu, Yuan-Qing
1 Wu, Yueh-Lin
1 Wu, Yuling
1 Wu, Yuzhou
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos